title: Breakthrough invasive aspergillosis in allogeneic haematopoietic  stem cell transplant recipients treated with caspofungin.
abstract: During the period January 2004 to April 2007, nine cases of breakthrough invasive aspergillosis occurred among 156 allogeneic haematopoietic stem cell transplant recipients receiving caspofungin therapy, mainly for empirical treatment of persisting fever. Voriconazole salvage therapy induced two complete responses. However, seven patients ultimately died a median of 5 weeks after diagnosis, including five patients with aspergillosis. This high incidence of breakthrough invasive aspergillosis in this patient population receiving caspofungin therapy warrants further investigation.
authors.affiliation: Hematology-Bone Marrow Transplant Unit, Saint-Louis Hospital, Université Paris VII, 1 avenue Claude Vellefaux, 75010 Paris, France.
authors.forename: Adrienne
authors.initials: A
authors.lastname: Madureira
authors.forename: Anne
authors.initials: A
authors.lastname: Bergeron
authors.forename: Claire
authors.initials: C
authors.lastname: Lacroix
authors.forename: Marie
authors.initials: M
authors.lastname: Robin
authors.forename: Vanderson
authors.initials: V
authors.lastname: Rocha
authors.forename: Régis Peffault
authors.initials: RP
authors.lastname: de Latour
authors.forename: Christèle
authors.initials: C
authors.lastname: Ferry
authors.forename: Agnès
authors.initials: A
authors.lastname: Devergie
authors.forename: Jordane
authors.initials: J
authors.lastname: Lapalu
authors.forename: Eliane
authors.initials: E
authors.lastname: Gluckmana
authors.forename: Gérard
authors.initials: G
authors.lastname: Socié
authors.forename: Mahmoud
authors.initials: M
authors.lastname: Ghannoum
authors.forename: Patricia
authors.initials: P
authors.lastname: Ribaud
mesh_terms: D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000382:microbiology / Q000401:mortality / Q000517:prevention & control*; D001230:Aspergillus / Q000187:drug effects*; D000077336:Caspofungin; D025141:Drug Resistance, Fungal; D054714:Echinocandins / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D055666:Lipopeptides; D011743:Pyrimidines / Q000627:therapeutic use; D014184:Transplantation, Homologous / Q000009:adverse effects*; D014230:Triazoles / Q000627:therapeutic use; D065819:Voriconazole
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D011743:Pyrimidines; D014230:Triazoles; D000077336:Caspofungin; D065819:Voriconazole